US 11419898
Combinatorial cancer immunotherapy
granted A61KA61K35/28A61K38/20
Quick answer
US patent 11419898 (Combinatorial cancer immunotherapy) held by Senti Biosciences, Inc. expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Senti Biosciences, Inc.
- Grant date
- Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K35/28, A61K38/20, A61K38/208, A61K48/005